Open Access

High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor‑positive breast cancer

  • Authors:
    • Eriko Katsuta
    • Ali A. Maawy
    • Li Yan
    • Kazuaki Takabe
  • View Affiliations

  • Published online on: August 12, 2019     https://doi.org/10.3892/or.2019.7275
  • Pages: 1413-1421
  • Copyright: © Katsuta et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There are conflicted experimental results on the role of bone morphogenetic proteins (BMPs) in cancer. Some results suggest that BMPs act as tumor suppressors while other findings indicate that BMPs are oncogenic factors. In the present study, we aimed to investigate the association of BMP expression and the survival of breast cancer patients utilizing The Cancer Genome Atlas (TCGA). High expression levels of BMP1 (P<0.001), BMP3 (P=0.002), BMP5 (P=0.002), BMP7 (P<0.001) and BMPR1A (P<0.001) were associated with better overall survival (OS). On the other hand, high expression levels of BMP6 (P<0.001), BMP8A (P=0.031), BMP8B (P<0.001) and BMPR1B (P=0.005) were associated with worse OS. Most of the BMPs demonstrated differential expression levels between normal and tumor tissues. High expression of BMP7 was found to be significantly associated with better prognosis in both estrogen receptor (ER)‑positive (ER+) (P<0.001) and ER‑negative (ER‑) tumors (P<0.001), whereas high expression of BMP6 was associated with better prognosis only in ER+ tumors (P=0.004); it was associated with worse prognosis in ER‑ tumors (P=0.006). In the ER+ tumors, high expression of BMP7 as well as BMP6 were associated with higher infiltration of anticancer immune cells and cytolytic activity. These results suggest that high expression levels of BMP7 as well as BMP6 possess higher anticancer immunity which results in better prognosis in ER+ breast cancer. In conclusion, BMP expression profiles may be useful for prognostication. Intervention in this pathway may serve to improve outcomes, manage metastatic disease and assist in clinical decision making on optimal therapy based on the risk of recurrence or metastasis.

References

1 

Guo X and Wang XF: Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 19:71–88. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA: Novel regulators of bone formation: Molecular clones and activities. Science. 242:1528–1534. 1988. View Article : Google Scholar : PubMed/NCBI

3 

Langenfeld E, Kong Y and Langenfeld J: Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 25:685–692. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Alarmo EL, Kuukasjärvi T, Karhu R and Kallioniemi A: A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat. 103:239–246. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL and Anderson RL: BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res. 74:5091–5102. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Guo D, Huang J and Gong J: Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer. Mol Cell Biochem. 363:179–190. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Alarmo EL, Pärssinen J, Ketolainen JM, Savinainen K, Karhu R and Kallioniemi A: BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett. 275:35–43. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Pickup MW, Hover LD, Guo Y, Gorska AE, Chytil A, Novitskiy SV, Moses HL and Owens P: Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis. Oncotarget. 6:22890–22904. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Yang L, Pang Y and Moses HL: TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31:220–227. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Lee GT, Jung YS, Ha YS, Kim JH, Kim WJ and Kim IY: Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Sci. 104:1027–1032. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, et al: Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 3:248–261. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Chin L, Andersen JN and Futreal PA: Cancer genomics: From discovery science to personalized medicine. Nat Med. 17:297–303. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI

15 

Terakawa T, Katsuta E, Yan L, Turaga N, McDonald KA, Fujisawa M, Guru KA and Takabe K: High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy. Oncotarget. 9:14207–14218. 2018. View Article : Google Scholar : PubMed/NCBI

16 

Hirose Y, Nagahashi M, Katsuta E, Yuza K, Miura K, Sakata J, Kobayashi T, Ichikawa H, Shimada Y, Kameyama H, et al: Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep. 8:108142018. View Article : Google Scholar : PubMed/NCBI

17 

Young J, Kawaguchi T, Yan L, Qi Q, Liu S and Takabe K: Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival. Oncotarget. 8:99978–99989. 2017. View Article : Google Scholar : PubMed/NCBI

18 

Hoki T, Katsuta E, Yan L, Takabe K and Ito F: Low DMT1 expression associates with increased oxidative phosphorylation and early recurrence in hepatocellular carcinoma. J Surg Res. 234:343–352. 2019. View Article : Google Scholar : PubMed/NCBI

19 

Sporn JC, Katsuta E, Yan L and Takabe K: Expression of microRNA-9 is associated with overall survival in breast cancer patients. J Surg Res. 233:426–435. 2019. View Article : Google Scholar : PubMed/NCBI

20 

Katsuta E, Qi Q, Peng X, Hochwald SN, Yan L and Takabe K: Pancreatic adenocarcinomas with mature blood vessels have better overall survival. Sci Rep. 9:13102019. View Article : Google Scholar : PubMed/NCBI

21 

Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res. 7:R953–R964. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ and Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI

24 

Katsuta E, Yan L, Nagahashi M, Raza A, Sturgill JL, Lyon DE, Rashid OM, Hait NC and Takabe K: Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res. 219:202–213. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H and Trajanoski Z: Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18:248–262. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N: Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 160:48–61. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Narayanan S, Kawaguchi T, Yan L, Peng X, Qi Q and Takabe K: Cytolytic activity score to assess anticancer immunity in colorectal cancer. Ann Surg Oncol. 25:2323–2331. 2018. View Article : Google Scholar : PubMed/NCBI

29 

Ye L, Bokobza S, Li J, Moazzam M, Chen J, Mansel RE and Jiang WG: Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Sci. 101:2137–2144. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, González Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, et al: Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial. Clin Cancer Res. 25:771–783. 2019. View Article : Google Scholar : PubMed/NCBI

31 

Athanasios F, Afrodite N, Effstratios P and Demetrios K: Co-expression of bone morphogenetic protein 6 with estrogen receptor a in endometriosis. Arch Gynecol Obstet. 285:1001–1007. 2012. View Article : Google Scholar : PubMed/NCBI

32 

Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, et al: Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER(+) breast cancer. FASEB J. 33:1644–1657. 2019. View Article : Google Scholar : PubMed/NCBI

33 

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP and Tamayo P: The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI

34 

Davies SR, Watkins G, Douglas-Jones A, Mansel RE and Jiang WG: Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance. J Exp Ther Oncol. 7:327–338. 2008.PubMed/NCBI

35 

Takahashi M, Otsuka F, Miyoshi T, Otani H, Goto J, Yamashita M, Ogura T, Makino H and Doihara H: Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol. 199:445–455. 2008. View Article : Google Scholar : PubMed/NCBI

36 

Alarmo EL, Korhonen T, Kuukasjärvi T, Huhtala H, Holli K and Kallioniemi A: Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol. 19:308–314. 2008. View Article : Google Scholar : PubMed/NCBI

37 

Yang S, Du J, Wang Z, Yuan W, Qiao Y, Zhang M, Zhang J, Gao S, Yin J, Sun B and Zhu T: BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells. BMC Cancer. 7:2112007. View Article : Google Scholar : PubMed/NCBI

38 

Du J, Yang S, An D, Hu F, Yuan W, Zhai C and Zhu T: BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res. 19:487–496. 2009. View Article : Google Scholar : PubMed/NCBI

39 

Lian WJ, Liu G, Liu YJ, Zhao ZW, Yi T and Zhou HY: Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer. Oncol Rep. 30:193–200. 2013. View Article : Google Scholar : PubMed/NCBI

40 

Tandon A, Sharma A, Rodier JT, Klibanov AM, Rieger FG and Mohan RR: BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PLoS One. 8:e664342013. View Article : Google Scholar : PubMed/NCBI

41 

Schmidt J, Weijdegård B, Mikkelsen AL, Lindenberg S, Nilsson L and Brännström M: Differential expression of inflammation-related genes in the ovarian stroma and granulosa cells of PCOS women. Mol Hum Reprod. 20:49–58. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 42 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Katsuta, E., Maawy, A.A., Yan, L., & Takabe, K. (2019). High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor‑positive breast cancer. Oncology Reports, 42, 1413-1421. https://doi.org/10.3892/or.2019.7275
MLA
Katsuta, E., Maawy, A. A., Yan, L., Takabe, K."High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor‑positive breast cancer". Oncology Reports 42.4 (2019): 1413-1421.
Chicago
Katsuta, E., Maawy, A. A., Yan, L., Takabe, K."High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor‑positive breast cancer". Oncology Reports 42, no. 4 (2019): 1413-1421. https://doi.org/10.3892/or.2019.7275